Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891006 | 0.85 | HPGD (0.44) | GAAALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL9890999 | 0.79 | CYP4F2 (0.35) | GAATHRBHTTFKBP1AMEN1 | |
| SCHEMBL9891008 | 0.79 | GNAI3 (0.36) | THRBMAPTMEN1KMT2A | |
| SCHEMBL9891000 | 0.77 | SMYD3 (0.37) | GAATHRBNOS3NOS2HTT | |
| SCHEMBL9891012 | 0.73 | KDM4E (0.36) | — | |
| SCHEMBL15247425 | 0.73 | HPGD (0.45) | GAASMN1; SMN2 | |
| SCHEMBL6750166 | 0.73 | HPGD (0.45) | GAASMN1; SMN2 | |
| SCHEMBL9389313 | 0.72 | HPGD (0.44) | GAAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL9212728 | 0.71 | GAA (0.53) | GAAL3MBTL1THRBATMNOS3 | |
| SCHEMBL15247133 | 0.70 | GNAI3 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142722-A1 | CONJUGATES OF CYTOTOXIC DRUGS | APOSENSE LTD. (IL) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142722-A1 | CONJUGATES OF CYTOTOXIC DRUGS | CD47, MCL1, BAD | GAA 144/4885L3MBTL1 1002/4885THRB 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.